QPPV.COM KNOWLEDGE ASSESSMENT

Proton Pump Inhibitors and Hypomagnesaemia: A Signal Evaluation

Test your understanding of the concepts covered by Proton Pump Inhibitors and Hypomagnesaemia: A Signal Evaluation.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which patient information would most strengthen assessment of alternative causes in an individual case?

The colour and shape of the PPI tablet Assessment of diuretic use, gastrointestinal losses, renal disease, alcohol use and nutritional status The number of other patients taking the same brand worldwide The patient's preference for tablets over capsules

Question 2 of 10 A safety professional sees one report of mild hypomagnesaemia in a PPI user with chronic diarrhoea and thiazide therapy. What is the most appropriate initial interpretation?

The PPI is definitely causal because hypomagnesaemia is a recognised signal The case is uninterpretable and should be discarded The case requires careful assessment of competing causes and clinical chronology before its causal weight is judged The case proves that thiazides do not contribute to magnesium loss

Question 3 of 10 What is the most appropriate regulatory interpretation of heterogeneous epidemiological findings alongside strong case-level dechallenge and rechallenge evidence?

The heterogeneous studies necessarily invalidate the case reports The case reports necessarily establish the population incidence The evidence streams address different aspects of the association and should be interpreted together Only the study with the largest sample size should determine the conclusion

Question 4 of 10 A patient develops severe hypomagnesaemia during long-term PPI treatment. Magnesium replacement is insufficient while the PPI continues, but serum magnesium normalises promptly after withdrawal. How should this observation be interpreted?

It provides meaningful positive dechallenge evidence It proves that the PPI caused the event in every exposed patient It excludes all possible concomitant causes It demonstrates that magnesium supplementation is ineffective in hypomagnesaemia

Question 5 of 10 Why should a pharmacovigilance team avoid deliberately rechallenging a patient solely to strengthen the evidence for this signal?

Rechallenge can never provide useful information Rechallenge may expose the patient to recurrence of a potentially serious reaction without clinical necessity Rechallenge is prohibited for all medicines under EU pharmacovigilance practice A positive rechallenge is weaker than an unverified spontaneous report

Question 6 of 10 A case of hypomagnesaemia is identified after six years of PPI treatment. What is the most appropriate causality interpretation?

The latency automatically excludes a causal relationship The latency is compatible with a cumulative depletion or absorption-related mechanism Only reactions occurring within 24 hours can be causally related The event should be attributed to age unless rechallenge occurs

Question 7 of 10 Which counterfactual observation would most weaken the proposed causal association?

Some cases occur after several years of exposure Cases include concomitant diuretic use There is no consistent improvement after withdrawal and no recurrence after re-exposure across well-documented cases Different observational studies use different definitions of hypomagnesaemia

Question 8 of 10 Which finding would most strongly distinguish PPI-associated intestinal magnesium malabsorption from renal magnesium wasting?

Appropriately low urinary magnesium excretion during profound hypomagnesaemia A history of intermittent PPI use Mildly reduced serum potassium Older age at the time of diagnosis

Question 9 of 10 What is the most defensible conclusion from repeated recurrence of hypomagnesaemia after switching between different PPIs?

The event is unrelated to PPIs because different products were involved The pattern supports a class effect, while not proving identical risk for every PPI Only the second PPI can be considered causal The recurrence proves a specific TRPM6 mutation in the patient

Question 10 of 10 Which clinical consequence would increase the priority of a PPI-associated hypomagnesaemia signal?

A transient change in appetite without biochemical abnormality QT prolongation with ventricular arrhythmia risk A mild, self-limited headache A stable serum sodium concentration

QPPV.com

Proton Pump Inhibitors and Hypomagnesaemia: A Signal Evaluation

Cookie Settings